Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Work In Process (2023 - 2024)

Historic Work In Process for Seres Therapeutics (MCRB) over the last 2 years, with Q2 2024 value amounting to $48.1 million.

  • Seres Therapeutics' Work In Process rose 91185.26% to $48.1 million in Q2 2024 from the same period last year, while for Jun 2024 it was $48.1 million, marking a year-over-year increase of 91185.26%. This contributed to the annual value of $25.2 million for FY2023, which is N/A changed from last year.
  • Seres Therapeutics' Work In Process amounted to $48.1 million in Q2 2024, which was up 91185.26% from $37.3 million recorded in Q1 2024.
  • Seres Therapeutics' 5-year Work In Process high stood at $48.1 million for Q2 2024, and its period low was $4.8 million during Q2 2023.